Optimizing topical therapy for psoriasis

References

• National Psoriasis Foundation. About Psoriasis. In: Learn. NPF: National Psoriasis Foundation, Portland, OR USA (2009).
   Google Scholar
• NIAMS. Questions and answers about psoriasis. In: Health Info: Psoriasis. NIAMS: National Institute of Arthritis and Musculoskeletal and Skin Diseases, MD, USA (2009).
   Google Scholar
• Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin. Dermatol.25(6), 547–554 (2007).
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol.20(4), 370–379 (2006).
   PubMed Web of Science ®Google Scholar
• Wu JJ, Weinstein GD. General guidelines for administration of topical agents in the treatment of mild-to-moderate psoriasis. In: Mild-to-Moderate Psoriasis (Second Edition). Koo JYM, Lee CS, Lebwohl MG (Eds). Informa Healthcare, NY, USA 11–21 (2009).
   Google Scholar
• Feldman SR. General approach to psoriasis treatment. In: Mild-to-Moderate Psoriasis (Second Edition). Koo JYM, Lee CS, Lebwohl MG (Eds). Informa Healthcare, NY, USA 5–10 (2009).
   Google Scholar
• Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J. Am. Acad. Dermatol.59(1), 27–33 (2008).
   PubMed Web of Science ®Google Scholar
• de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J. Investig. Dermatol. Symp. Proc.9(2), 140–147 (2004).
   PubMed Web of Science ®Google Scholar
• Magin P, Adams J, Heading G, Pond D, Smith W. The psychological sequelae of psoriasis: results of a qualitative study. Psychol. Health Med.14(2), 150–161 (2009).
   PubMed Web of Science ®Google Scholar
• Callen JP, Krueger GG, Lebwohl M et al. AAD consensus statement on psoriasis therapies. J. Am. Acad. Dermatol.49(5), 897–899 (2003).
   PubMed Web of Science ®Google Scholar
• Strowd LC, Yentzer BA, Fleischer AB, Jr., Feldman SR. Increasing use of more potent treatments for psoriasis. J. Am. Acad. Dermatol.60(3), 478–481 (2009).
   PubMed Web of Science ®Google Scholar
• Tremblay JF, Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J. Cutan. Med. Surg.6(3 Suppl.), 8–11 (2002).
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J. Am. Acad. Dermatol.60(4), 643–659 (2009).
   PubMed Web of Science ®Google Scholar
• Givan J, Pearce D, Feldman SR. Topical Corticosteroids. In: Mild-to-Moderate Psoriasis (Second Edition). Koo JYM, Lee CS, Lebwohl MG (Eds). Informa Healthcare, NY, USA 23–39 (2009).
   Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol.54(1), 1–15 (2006).
   PubMed Web of Science ®Google Scholar
• Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J. Am. Acad. Dermatol.41(4), 546–549 (1999).
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gold MH, Zib B, Davis MW. Clobetasol propionate emulsion formulation foam 0.05%: review of Phase II open-label and Phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J. Am. Acad. Dermatol.59(3), 448–454, e441 (2008).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J. Cutan. Med. Surg.7(3), 185–192 (2003).
   PubMed Web of Science ®Google Scholar
• Tan J, Thomas R, Wang B et al. Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis. Cutis83(3), 157–164 (2009).
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J. Dermatol. Treat.17(2), 90–95 (2006).
   PubMed Web of Science ®Google Scholar
• Mraz S, Leonardi C, Colon LE, JohnsonLA. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis. J. Dermatol. Treat.19(6), 354–359 (2008).
   PubMed Web of Science ®Google Scholar
• Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. Cutis80(5 Suppl.), 20–28 (2007).
   PubMed Web of Science ®Google Scholar
• Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J. Am. Acad. Dermatol.52(1), 27–31 (2005).
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB Jr, Feldman SR. Psoriasis treatment in the United States at the end of the 20th Century. Int. J. Dermatol.45(4), 370–374 (2006).
   PubMed Web of Science ®Google Scholar
• Lee CS. Vitamin D3 Analogs. In: Mild-to-Moderate Psoriasis (Second Edition). Koo JYM, Lee CS, Lebwohl MG (Eds). Informa Healthcare, NY, USA 41–55 (2009).
   Google Scholar
• Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: a review of its use in the management of psoriasis. Am. J. Clin. Dermatol.2(2), 95–120 (2001).
   PubMedGoogle Scholar
• Molin L. Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology198(4), 375–381 (1999).
   PubMed Web of Science ®Google Scholar
• Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin. Ther.22(10), 1225–1238 (2000).
   PubMed Web of Science ®Google Scholar
• Braun GS, Witt M, Mayer V, Schmid H. Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment. Int. J. Dermatol.46(12), 1315–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Duvic M. Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis. Expert Opin. Investig. Drugs.6(10), 1537–1551 (1997).
   PubMedGoogle Scholar
• Duvic M, Asano AT, Hager C, Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J. Am. Acad. Dermatol.39(4 Pt 2), S129–S133 (1998).
   Web of Science ®Google Scholar
• Weinstein GD, Krueger GG, Lowe NJ et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J. Am. Acad. Dermatol.37(1), 85–92 (1997).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Drake LA, Elias PM et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch. Dermatol.134(1), 57–60 (1998).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ast E, Callen JP et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J. Am. Acad. Dermatol.38(5 Pt 1), 705–711 (1998).
   PubMed Web of Science ®Google Scholar
• Kaur I, Dogra S, Jain R, Kumar B. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian J. Dermatol. Venereol. Leprol.74(5), 471–474 (2008).
   PubMed Web of Science ®Google Scholar
• Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J. Cutan. Med. Surg.6(2), 95–102 (2002).
   PubMed Web of Science ®Google Scholar
• Poulin YP. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis63(1), 41–48 (1999).
   PubMed Web of Science ®Google Scholar
• Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream BID. in the treatment of plaque psoriasis. Int. J. Dermatol.40(3), 210–212 (2001).
   PubMed Web of Science ®Google Scholar
• Dhawan SS, Blyumin ML, Pearce DJ, Feldman SR. Tazarotene cream (0.1%) in combination with betamethasone valerate foam (0.12%) for plaque-type psoriasis. J. Drugs Dermatol.4(2), 228–230 (2005).
   PubMedGoogle Scholar
• Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J. Am. Acad. Dermatol.46(6), 907–913 (2002).
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J. Am. Acad. Dermatol.43(2 Pt 3), S43–S46 (2000).
   PubMedGoogle Scholar
• Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis68(5), 355–358 (2001).
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm. Venereol.87(2), 167–168 (2007).
   PubMed Web of Science ®Google Scholar
• Diluvio L, Campione E, Paterno EJ, Mordenti C, El Hachem M, Chimenti S. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr. Dermatol.24(3), 332–333 (2007).
   PubMed Web of Science ®Google Scholar
• Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br. J. Dermatol.149(1), 207–209 (2003).
   PubMed Web of Science ®Google Scholar
• Tzaneva S, Honigsmann H, Tanew A, Seeber A. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br. J. Dermatol.147(4), 748–753 (2002).
   PubMed Web of Science ®Google Scholar
• Schiener R, Behrens-Williams SC, Pillekamp H, Kaskel P, Peter RU, Kerscher M. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. Br. J. Dermatol.143(6), 1275–1278 (2000).
   PubMed Web of Science ®Google Scholar
• Koo JY, Lowe NJ, Lew-Kaya DA et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J. Am. Acad. Dermatol.43(5 Pt 1), 821–828 (2000).
   PubMed Web of Science ®Google Scholar
• Behrens S, Grundmann-Kollmann M, Schiener R, Peter RU, Kerscher M. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J. Am. Acad. Dermatol.42(3), 493–495 (2000).
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JY, Krueger GG et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J. Am. Acad. Dermatol.48(5), 760–767 (2003).
   PubMed Web of Science ®Google Scholar
• Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J. Am. Acad. Dermatol.41(1), 51–59 (1999).
   PubMed Web of Science ®Google Scholar
• Veraldi S, Caputo R, Pacifico A, Peris K, Soda R, Chimenti S. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology212(3), 235–237 (2006).
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Breneman DL, Goffe BS et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J. Am. Acad. Dermatol.39(4 Pt 1), 590–596 (1998).
   PubMed Web of Science ®Google Scholar
• McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J.19(8), 1012–1014 (2005).
   PubMed Web of Science ®Google Scholar
• Fitzmaurice S, Becker E, Koo JYM, Sivanesan P. Treatment of mild-to-moderate psoriasis with coal tar, anthralin, salicylic acid, and lactic acid. In: Mild-to-Moderate Psoriasis (Second Edition). Koo JYM, Lee CS, Lebwohl MG (Eds). Informa Healthcare, NY, USA 91–102 (2009).
   Google Scholar
• de Korte J, van der Valk PG, Sprangers MA et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br. J. Dermatol.158(2), 375–381 (2008).
   PubMed Web of Science ®Google Scholar
• Kucharekova M, Schalkwijk J. Dithranol. In: Irritant Dermatitis (First Edition). Chew AL, Maibach HI (Eds). Springer, Berlin, Germany 317–322 (2006).
   Google Scholar
• Arnold WP. Tar. Clin. Dermatol.15(5), 739–744 (1997).
   PubMed Web of Science ®Google Scholar
• Paghdal KV, Schwartz RA. Topical tar: back to the future. J. Am. Acad. Dermatol. (2009).
   PubMedGoogle Scholar
• Lee E, Koo J. Modern modified ‘ultra’ Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J. Dermatolog. Treat.16(2), 102–107 (2005).
   PubMed Web of Science ®Google Scholar
• Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J. Dermatolog. Treat.15(1), 14–22 (2004).
   PubMedGoogle Scholar
• National Psoriasis Foundation. Coal tar products target of California lawsuit alleging cancer risk. In: National Psoriasis Foundation News Archive. National Psoriasis Foundation, Portland, OR, USA (2001).
   Google Scholar
• National Psoriasis Foundation. UVB phototherapy. In: Phototherapy. National Psoriasis Foundation, OR, USA (2009)
   Google Scholar
• Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin. Dermatol.26(4), 380–386 (2008).
   PubMed Web of Science ®Google Scholar
• Koo J, Cuffie CA, Tanner DJ et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin. Ther.20(2), 283–291 (1998).
   PubMed Web of Science ®Google Scholar
• Elie R, Durocher LP, Kavalec EC. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J. Int. Med. Res.11(2), 108–112 (1983).
   PubMed Web of Science ®Google Scholar
• Krochmal L, Wang JC, Patel B, Rodgers J. Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. J. Am. Acad. Dermatol.21(5 Pt 1), 979–984 (1989).
   PubMed Web of Science ®Google Scholar
• de Leeuw J, Tank B, Bjerring PJ, Koetsveld S, Neumann M. Concomitant treatment of psoriasis of the hands and feet with pulsed dye laser and topical calcipotriol, salicylic acid, or both: a prospective open study in 41 patients. J. Am. Acad. Dermatol.54(2), 266–271 (2006).
   PubMed Web of Science ®Google Scholar
• Ilknur T, Akarsu S, Aktan S, Ozkan S. Comparison of the effects of pulsed dye laser, pulsed dye laser + salicylic acid, and clobetasole propionate + salicylic acid on psoriatic plaques. Dermatol. Surg.32(1), 49–55 (2006).
   PubMed Web of Science ®Google Scholar
• Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch. Dermatol.141(1), 43–46 (2005).
   PubMed Web of Science ®Google Scholar
• Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int. J. Dermatol.38(1), 16–24 (1999).
   PubMed Web of Science ®Google Scholar
• McClain R, Yentzer BA, Feldman SR. Keratolytics for psoriasis: are they necessary? Dermatol. Online J.15(1), 11 (2009).
   PubMedGoogle Scholar
• Kostarelos K, Teknetzis A, Lefaki I, Ioannides D, Minas A. Double-blind clinical study reveals synergistic action between a-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis. J. Eur. Acad. Dermatol. Venereol.14(1), 5–9 (2000).
   PubMed Web of Science ®Google Scholar
• Uy JJ, Joyce AM, Nelson JP, West B, Montague JR. Ammonium lactate 12% lotion versus a liposome-based moisturizing lotion for plantar xerosis: a double-blind comparison study. J. Am. Podiatr. Med. Assoc.89(10), 502–505 (1999).
   PubMed Web of Science ®Google Scholar
• Jennings MB, Logan L, Alfieri DM, Ross CF, Goodwin S, Lesczczynski C. A comparative study of lactic acid 10% and ammonium lactate 12% lotion in the treatment of foot xerosis. J. Am. Podiatr. Med. Assoc.92(3), 143–148 (2002).
   PubMed Web of Science ®Google Scholar
• Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin. Pharmacother.5(3), 643–655 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobi A, Braeutigam M, Mahler V, Schultz E, Hertl M. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology216(2), 133–136 (2008).
   PubMed Web of Science ®Google Scholar
• Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br. J. Dermatol.141(2), 264–273 (1999).
   PubMed Web of Science ®Google Scholar
• Lan CC, Yu HS, Wu CS, Kuo HY, Chai CY, Chen GS. FK506 inhibits tumour necrosis factor-α secretion in human keratinocytes via regulation of nuclear factor-κB. Br. J. Dermatol.153(4), 725–732 (2005).
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Graeber M, Brautigam M et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. J. Dermatol.139(6), 992–996 (1998).
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm. Venereol.83(5), 351–353 (2003).
   PubMed Web of Science ®Google Scholar
• Gribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J. Am. Acad. Dermatol.51(5), 731–738 (2004).
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Landry CA. Topical calcineurin inhibitors. In: Mild-to-Moderate Psoriasis (Second Edition). Koo JYM, Lee CS, Lebwohl MG (Eds). Informa Healthcare, NY, USA 83–90 (2009).
   Google Scholar
• Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. J. Pharm.269(1), 29–35 (2004).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J. Am. Acad. Dermatol.51(5), 723–730 (2004).
   PubMed Web of Science ®Google Scholar
• Freeman AK, Linowski GJ, Brady C et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol.48(4), 564–568 (2003).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur. J. Dermatol.13(5), 471–473 (2003).
   PubMed Web of Science ®Google Scholar
• Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E, Umbert Millet P. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J. Drugs Dermatol.5(4), 334–336 (2006).
   PubMedGoogle Scholar
• Rallis E, Nasiopoulou A, Kouskoukis C et al. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp. Clin. Res.31(4), 141–145 (2005).
   PubMedGoogle Scholar
• Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J. Cutan. Med. Surg.12(5), 230–234 (2008).
   PubMed Web of Science ®Google Scholar
• Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g-1 ointment and tacrolimus 0.3 mg g-1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br. J. Dermatol.157(5), 1005–1012 (2007).
   PubMed Web of Science ®Google Scholar
• Kreuter A, Sommer A, Hyun J et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch. Dermatol.142(9), 1138–1143 (2006).
   PubMedGoogle Scholar
• Ahn SJ, Oh SH, Chang SE, Choi JH, Koh JK. A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. J. Eur. Acad. Dermatol. Venereol.20(10), 1332–1334 (2006).
   PubMed Web of Science ®Google Scholar
• Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int. J. Clin. Pract.59(8), 969–974 (2005).
   PubMed Web of Science ®Google Scholar
• Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol. Online J.12(2), 7 (2006).
   PubMedGoogle Scholar
• Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J. Eur. Acad. Dermatol. Venereol.18(6), 742–743 (2004).
   PubMed Web of Science ®Google Scholar
• Canpolat F, Cemil BC, Tatlican S, Eskioglu F, Oktay M, Alper M. Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant. Eur. J. Dermatol.19(2), 168–169 (2009).
   PubMed Web of Science ®Google Scholar
• Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr. Dermatol.24(1), 76–80 (2007).
   PubMed Web of Science ®Google Scholar
• Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J. Am. Acad. Dermatol.53(4), 713–716 (2005).
   PubMed Web of Science ®Google Scholar
• Koo JY. Using topical multimodal strategies for patients with psoriasis. Cutis79(1 Suppl. 2), 11–17 (2007).
   PubMedGoogle Scholar
• Menter MA, See JA, Amend WJ et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7–9, 1994. J. Am. Acad. Dermatol.34(2 Pt 1), 315–321 (1996).
   PubMed Web of Science ®Google Scholar
• Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J. Am. Acad. Dermatol.53(1 Suppl. 1), S17–S25 (2005).
   PubMed Web of Science ®Google Scholar
• Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J. Am. Acad. Dermatol.41(3 Pt 2), S25–S28 (1999).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J. Am. Acad. Dermatol.50(3), 416–430 (2004).
   PubMed Web of Science ®Google Scholar
• Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J. Am. Acad. Dermatol.53(1 Suppl. 1), S50–58 (2005).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int. J. Dermatol.39(1), 41–44 (2000).
   PubMed Web of Science ®Google Scholar
• Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short and long-term outcomes. J. Am. Acad. Dermatol.55(4), 637–641 (2006).
   PubMed Web of Science ®Google Scholar
• Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J. Am. Acad. Dermatol.38(6 Pt 1), 1010–1011 (1998).
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Corvari L. Compatibility of topical therapies for psoriasis: challenges and innovations. Cutis79(1 Suppl. 2), 5–10 (2007).
   PubMedGoogle Scholar
• Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J. Drugs Dermatol.8(1), 52–57 (2009).
   PubMed Web of Science ®Google Scholar
• Jemec GB, Ganslandt C, Ortonne JP et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J. Am. Acad. Dermatol.59(3), 455–463 (2008).
   PubMed Web of Science ®Google Scholar
• Dando TM, Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am. J. Clin. Dermatol.6(4), 255–272 (2005).
   PubMed Web of Science ®Google Scholar
• Hecker D, Worsley J, Yueh G, Lebwohl M. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J. Am. Acad. Dermatol.42(6), 1008–1011 (2000).
   PubMed Web of Science ®Google Scholar
• Levitt J, Feldman T, Riss I, Leung OT. Compatibility of desoximetasone and tacrolimus. J. Drugs Dermatol.2(6), 640–642 (2003).
   PubMedGoogle Scholar
• Feldman SR, Horn EJ, Balkrishnan R et al. Psoriasis: improving adherence to topical therapy. J. Am. Acad. Dermatol.59(6), 1009–1016 (2008).
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA288(22), 2868–2879 (2002).
   PubMed Web of Science ®Google Scholar
• Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J. Am. Acad. Dermatol.51(2), 212–216 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J. Am. Acad. Dermatol.57(1), 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Diffey BL. Sunscreens, suntans and skin cancer. People do not apply enough sunscreen for protection. BMJ313(7062), 942 (1996).
   PubMedGoogle Scholar
• Hoch HE, Busse KL, Dellavalle RP. Consumer empowerment in dermatology. Dermatol. Clin.27(2), 177–183, vii (2009).
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch. Dermatol.140, 408–414 (2004).
   PubMed Web of Science ®Google Scholar
• Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J. Am. Acad. Dermatol.53(1 Suppl. 1), S59–S69 (2005).
   PubMed Web of Science ®Google Scholar